Literature DB >> 12937020

In vitro activities of a new lipopeptide, HMR 1043, against susceptible and resistant gram-positive isolates.

Pascale Bemer1, Marie-Emmanuelle Juvin, Andre Bryskier, Henri Drugeon.   

Abstract

The purpose of this study was to compare the activity of HMR 1043 with those of daptomycin and teicoplanin against gram-positive isolates. Susceptibility tests were performed for 52 strains, 26 parental strains, including staphylococcal, streptococcal, enterococcal, and listerial strains, and 26 HMR 1043-resistant mutants obtained from parental strains by using the Szybalski method. Agar dilution and disk diffusion susceptibility tests were performed by the procedures outlined by the NCCLS. HMR 1043 demonstrated good activity against susceptible and resistant gram-positive bacteria. The activity of HMR 1043 in vitro was less influenced by the presence of calcium ions than that of daptomycin. Susceptibility test breakpoints were not defined because of the poor correlation coefficients obtained with the different disks tested.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12937020      PMCID: PMC182620          DOI: 10.1128/AAC.47.9.3025-3029.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers.

Authors:  A L Barry; P C Fuchs; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Diagn Microbiol Infect Dis       Date:  2000-09       Impact factor: 2.803

3.  Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

4.  In-vitro activity of LY146032 against Staphylococcus aureus and S. epidermidis.

Authors:  P E Coudron; J L Johnston; G L Archer
Journal:  J Antimicrob Chemother       Date:  1987-10       Impact factor: 5.790

5.  In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.

Authors:  G M Eliopoulos; S Willey; E Reiszner; P G Spitzer; G Caputo; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

6.  In vitro activity of LY146032 (daptomycin), a new peptolide.

Authors:  F Ehlert; H C Neu
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

7.  In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.

Authors:  M J Rybak; E Hershberger; T Moldovan; R G Grucz
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

8.  Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens.

Authors:  D R Snydman; N V Jacobus; L A McDermott; J R Lonks; J M Boyce
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

9.  Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium.

Authors:  N Mobarakai; J M Quale; D Landman
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

10.  Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci.

Authors:  A Louie; A L Baltch; W J Ritz; R P Smith; M Asperilla
Journal:  Chemotherapy       Date:  1993 Sep-Oct       Impact factor: 2.544

  10 in total
  1 in total

1.  Vancomycin-resistant Enterococcus faecium: catheter colonization, esp gene, and decreased susceptibility to antibiotics in biofilm.

Authors:  Issam I Raad; Hend A Hanna; Maha Boktour; Gassan Chaiban; Ray Y Hachem; Tanya Dvorak; Russell Lewis; Barbara E Murray
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.